Patents Assigned to Osiris Therapeutics
-
Patent number: 10272116Abstract: Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: GrantFiled: February 5, 2014Date of Patent: April 30, 2019Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Patent number: 10265344Abstract: Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: GrantFiled: May 30, 2014Date of Patent: April 23, 2019Assignee: Osiris Therapeutics, Inc.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Patent number: 10258650Abstract: Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: GrantFiled: November 1, 2013Date of Patent: April 16, 2019Assignee: Osiris Therapeutics, Inc.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Patent number: 9956248Abstract: This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: GrantFiled: November 1, 2013Date of Patent: May 1, 2018Assignee: Osiris Therapeutics, Inc.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin Qiang Kuang, Jennifer Michelle Marconi
-
Publication number: 20150010609Abstract: Provided herein is a placental membrane product comprising an immunocompatible chorionic membrane. Such placental membrane products can be cryopreserved and contain therapeutic factors and viable cells after thawing. The placental membrane products are useful in wound healing or tissue repair/regeneration as they are capable of promoting angiogenesis, reducing inflammation, reducing scar formation, and other methods that promote healing. The present technology relates to products to protect injured or damaged tissue, or as a covering to exclude bacteria, to inhibit bacterial activity, or to promote healing or growth of tissue. The field also relates to methods of manufacturing and methods of use of such membrane-derived products.Type: ApplicationFiled: May 7, 2014Publication date: January 8, 2015Applicant: Osiris Therapeutics, Inc.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Publication number: 20150010610Abstract: Provided herein is a placental membrane product comprising an immunocompatible amniotic membrane. Such placental membrane products can be cryopreserved and contain therapeutic factors and viable cells after thawing. The placental membrane products are useful in wound healing and tissue repair/regeneration as they are capable of promoting angiogenesis, reducing inflammation, inhibiting proteases and free radical oxidation, reducing scar formation, and other methods that promote healing. The present technology relates to products to protect injured or damaged tissue, or as a covering to prevent adhesions, to exclude bacteria, to inhibit bacterial activity, and/or to promote healing or growth of tissue. The field also relates to methods of manufacturing and methods of use of such membrane-derived products.Type: ApplicationFiled: May 7, 2014Publication date: January 8, 2015Applicant: OSIRIS THERAPEUTICS, INC.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Publication number: 20150010506Abstract: This invention provides a therapeutic placental composition comprising placental cells and other placental components derived from placental tissue. A cryopreserved placental composition is also provided. The placental compositions can be used to stimulate and promote angiogenesis, reduce inflammation, and to reduce scar formation, among others. The placental tissue can optionally be an amnion, chorion, a trophoblast-depleted chorion, umbilical cord, Wharton's jelly, placental cotyledon, and/or maternal decidua. The placental composition of the present invention is useful in treating a patient with a tissue injury (e.g., wound or burn) by applying the placental composition to the injury or in close proximity. Placental compositions may also be used to promote or increase regeneration of tissue. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: ApplicationFiled: May 7, 2014Publication date: January 8, 2015Applicant: OSIRIS THERAPEUTICS, INC.Inventors: Timothy Jansen, Samson Tom, Alla Danilkovitch, Dana Yoo, Jaime Zerhusen, Gabriele Putz Todd, Amy Elizabeth Johnson
-
Publication number: 20140301986Abstract: Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: ApplicationFiled: May 30, 2014Publication date: October 9, 2014Applicant: Osiris Therapeutics, Inc.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Publication number: 20140294777Abstract: Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: ApplicationFiled: February 5, 2014Publication date: October 2, 2014Applicant: OSIRIS THERAPEUTICS, INC.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Publication number: 20140140966Abstract: Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: ApplicationFiled: November 1, 2013Publication date: May 22, 2014Applicant: Osiris Therapeutics, Inc.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin Qiang Kuang, Jennifer Michelle Marconi
-
Publication number: 20140127317Abstract: Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: ApplicationFiled: November 1, 2013Publication date: May 8, 2014Applicant: Osiris Therapeutics, Inc.Inventors: Timothy Jansen, Samson Tom, Alla Danilkovitch, Dana Yoo, Jaime Zerhusen
-
Publication number: 20140127177Abstract: This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: ApplicationFiled: November 1, 2013Publication date: May 8, 2014Applicant: Osiris Therapeutics, Inc.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin Qiang Kuang, Jennifer Michelle Marconi
-
Publication number: 20140037598Abstract: This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: ApplicationFiled: October 17, 2013Publication date: February 6, 2014Applicant: Osiris Therapeutics, Inc.Inventors: Timothy Jansen, Samson Tom, Alla Danilkovitch, Dana Yoo, Jaime Zerhusen
-
Publication number: 20140030309Abstract: This invention provides disrupted cartilage products, methods of manufacturing disrupted cartilage products, and methods of treating a subject comprising administering a cartilage product. The cartilage products are manufactured by a method comprising disrupting a collagen matrix, e.g. to produce a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.Type: ApplicationFiled: July 11, 2013Publication date: January 30, 2014Applicant: Osiris Therapeutics, Inc.Inventors: Dana Sue Yoo, Jin-Qiang Kuang, Jaime Paden, Scott A. Maxson, Alla Danilkovitch, Erasmo Lopez, Samson Tom
-
Publication number: 20140030235Abstract: A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal.Type: ApplicationFiled: July 26, 2013Publication date: January 30, 2014Applicant: Osiris Therapeutics, Inc.Inventors: Timothy Varney, Charles Randal Mills, Alla Danilkovitch
-
Patent number: 8486695Abstract: Mesenchymal stem cells which express TNF-? receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.Type: GrantFiled: February 22, 2012Date of Patent: July 16, 2013Assignee: Osiris Therapeutics, Inc.Inventors: Alla Danilkovitch, Diane Carter, Alicia Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy
-
Publication number: 20130131804Abstract: A method of repairing and/or stabilizing a joint by administering mesenchymal stem cells to the joint. Such a method provides for the regeneration of cartilaginous tissue in the joint, including meniscal tissue.Type: ApplicationFiled: January 16, 2013Publication date: May 23, 2013Applicant: OSIRIS THERAPEUTICS, INC.Inventor: OSIRIS THERAPEUTICS, INC.
-
Patent number: 8158120Abstract: Disclosed are compositions and methods for repairing and/or regenerating cardiac tissue by administering adult bone marrow-derived stem cells to an individual. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.Type: GrantFiled: March 17, 2010Date of Patent: April 17, 2012Assignee: Osiris Therapeutics, Inc.Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay
-
Patent number: 8158121Abstract: Disclosed is a method for producing cardiomyocytes in vivo by administering to the heart of an individual a cardiomyocyte producing amount of mesenchymal stem cells. These cells can be administered as a liquid injectible or as a preparation of cells in a matrix which is or becomes solid or semi-solid. The cells can be genetically modified to enhance myocardial differentiation and integration. Also disclosed is a method for replacing cells ex vivo in a heart valve for implantation.Type: GrantFiled: January 25, 2011Date of Patent: April 17, 2012Assignee: Osiris Therapeutics, Inc.Inventors: Mark F. Pittenger, Stephen L. Gordon, Alastair Morgan Mackay, Bradley J. Martin
-
Publication number: 20120053144Abstract: The present invention is directed to methods of treating eye disease. In one embodiment, the method can comprise administering a bioconjugate to a subject to treat the eye disease, where the bioconjugate comprises a taxane covalently bonded to a cobalamin. Additionally, the bioconjugate can be dissolved in an aqueous solution prior to administration.Type: ApplicationFiled: January 27, 2010Publication date: March 1, 2012Applicant: Osiris Therapeutics, Inc.Inventors: John R. Gebhard, Dinesh Patel